# Phase 411: Tier 1+ #5 Cancer 深掘り — K_cancer framework

## Pass-1 #5 (Cancer, DOI 20151447) を引き継ぐ

Pass-1 #5 では:
- Cancer biology (hallmarks Hanahan-Weinberg 2000, 2011)
- Immunotherapy (CTLA-4, PD-1/PD-L1, James Allison Nobel 2018)
- CAR-T (Kymriah 2017, Yescarta, Carvykti)
- CRISPR-Cas9 (Doudna-Charpentier Nobel 2020)
- 言及範囲

を扱ったが、**K_cancer の operator-algebraic 定義**、**Tumor Heterogeneity Modular Hamiltonian**、**Single-cell RNA-seq + Pan-Cancer Atlas 統合** までは踏み込まなかった。

## Tier 1+ #5 の中心仮説

```
K_cancer = -log ρ_tumor
  where ρ_tumor is the density operator over tumor cell mutation/expression profiles
  
意味: tumor の heterogeneity (cellular diversity) を量化
```

## 全体構想 (Phase 411-426, 16 phases)

```
Phase 411: 開幕 + K_cancer framework 全体構想 ← 本ノート
Phase 412: Tumor heterogeneity operator-algebraic view
Phase 413: K_cancer = -log ρ_tumor 厳密定義
Phase 414: Mutational landscape (TCGA, ICGC) と K_cancer
Phase 415: Immune evasion (PD-1/PD-L1, CTLA-4) ITU 解釈
Phase 416: CAR-T (Kymriah, Yescarta, Carvykti) ITU framework
Phase 417: CRISPR-Cas9 (Casgevy 2023.12 first FDA) 接続
Phase 418: Metastasis modular flow
Phase 419: Single-cell RNA-seq + K_cancer measurement
Phase 420: Cancer vaccines (mRNA BioNTech/Moderna)
Phase 421: Liquid biopsy (Grail Galleri, Guardant Health)
Phase 422: Cancer atlases (HCA, HuBMAP, Pan-Cancer Atlas)
Phase 423: Pass-2 ロードマップ + budget
Phase 424: 10 falsifiable predictions
Phase 425: 45-vertex polytope #5 refresh + 数値検証 (toy tumor heterogeneity)
Phase 426: まとめ + Tier 1+ #6 Aging への接続
```

## Tier 1+ #5 の 4 つの中心仮説 (H_O1-H_O4)

### H_O1: Tumor is operator-algebraic state

```
Tumor T は density operator ρ_tumor で記述:
  ρ_tumor = density over cell mutation/expression profiles
  H_tumor = L²(Cell types × Mutations × Gene expression)
  
Heterogeneity ⇔ rank of ρ_tumor (effective cell type count)
```

### H_O2: K_cancer = malignancy 量化

```
⟨K_cancer⟩ = -Tr[ρ_tumor log ρ_tumor]
           = effective diversity of tumor cell population

Hypothesis:
  Benign tumor: ⟨K_cancer⟩ 低い (homogeneous)
  Malignant tumor: ⟨K_cancer⟩ 高い (heterogeneous)
  Late-stage: K_cancer maximum (multiple sub-clones)
```

### H_O3: Treatment response ⇔ K_cancer modular flow

```
治療 (chemotherapy, targeted therapy, immunotherapy):
  ρ_tumor → ρ_tumor^{treatment}
  
Resistance emergence ⇔ K_cancer increases (selection for resistant clones)
Successful treatment ⇔ K_cancer → 0 (complete remission)

ITU view: 治療効果 = δS(ρ_tumor) = δ⟨K_cancer⟩
```

### H_O4: Pan-Cancer Atlas reveals K_cancer universal patterns

```
TCGA (The Cancer Genome Atlas, 2006-2018): 11,000+ tumors, 33 cancer types
ICGC (International Cancer Genome Consortium): 50+ countries

Pan-Cancer Analysis:
  Common K_cancer signatures across types
  Tissue-specific K_cancer "fingerprints"
  Cross-cancer therapy implications
```

## 反証可能性

```
H_O1 反証: tumor heterogeneity が density operator で記述不可
H_O2 反証: K_cancer と malignancy が無相関 (specific cancer types で)
H_O3 反証: treatment 効果と K_cancer modular flow 無関係
H_O4 反証: Pan-Cancer K_cancer pattern が一致しない

Single-cell RNA-seq data (HCA, HuBMAP) で test 可能。
```

## なぜ Pass-1.5 で深掘りする意義があるか

```
Pass-1 #5 (2025): "Cancer biology + immunotherapy + CAR-T" の概念整理
Pass-1.5 #5 (2026):
  - K_cancer = -log ρ_tumor 厳密定義
  - Tumor Heterogeneity Modular Hamiltonian (新提案)
  - Single-cell RNA-seq での K_cancer 直接測定 protocol
  - Immune evasion (PD-1/PD-L1) ITU 解釈
  - CAR-T resistance prediction via K_cancer modular flow
  - Casgevy 2023.12 (first FDA CRISPR therapy) 接続
  - Liquid biopsy + K_cancer biomarker
```

## 2024 cancer landscape

```
WHO global cancer 2024:
  20M new cases/year, 10M deaths
  Lung, breast, colorectal, prostate, stomach top 5

Major FDA approvals 2023-2024:
  - Lecanemab (Alzheimer, 2023.7)
  - Casgevy (sickle cell, 2023.12) ★ first CRISPR
  - Imdelltra (Tarlatamab small cell lung, 2024.5)
  - Tovorafenib (pediatric glioma, 2024.4)
  - Eli Lilly Donanemab (Alzheimer 2024.7)
  - Kisqali (breast cancer adjuvant, 2024.9)

Major industry:
  Roche $59B revenue 2023
  Pfizer $58B
  Merck (Keytruda $25B 2023 best-selling drug)
  BMS, AstraZeneca, Novartis, Eli Lilly
```

---

#情報理論的統一理論 #ITU #Pass1.5 #Tier1plus #Cancer #K_cancer #Oncology #Phase411
